Search
Close this search box.

HIV Management Guide for Clinical Care

HIV Management Guide for Clinical Care

Search
Close this search box.

Biomedical prevention

Management > Biomedical prevention > References

Sections

Sections

References

  1. Remis RS, Alary M, Liu J, Kaul R, Palmer RWH. HIV transmission among men who have sex with men due to condom failure. PLOS ONE 2014; 9: e107540.
  2. Australian Clinical Supervision Association (ACSA). Clinical Supervision: A Working Definition. ACSA Definitions Report. Forest Lake, Qld, 2014. URL (last accessed on 30 October 2019): http://clinicalsupervision.org.au/wp-content/uploads/2014/10/ACSA-Definitions-Report-Final-2014.pdf.
  3. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. New Engl J Med 1997; 337: 1485-1490.
  4. Irvine C, Egan KJ, Shubber Z, et al. Efficacy of HIV postexposure prophylaxis: systematic review and meta-analysis of nonhuman primate studies. CID 2015; 60: S165-S169.
  5. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.  New Engl J Med 1994; 331: 1173-1180.
  6. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS 2008; 22: 973–981.
  7. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl J Med 2011; 365: 493-505.
  8. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl J Med 2010; 363: 2587-2599.
  9. Baeten JM, Donnell D, Ndase P, et al. Antriretroviral prophylaxis in heterosexual men and women. New Engl J Med 2012; 367: 399- 410.
  10. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381:2083-2090.
  11. Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397–1404.
  12. Gilliam BL. Methods of culturing HIV-1 from semen. Methods Mol Med 1999; 17:51–57.
  13. Dyer JR, Gilliam BL, Eron JJ Jr, et al. Quantitation of human immunodeficiency virus type 1 RNA in cell-free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J Virol Methods 1996; 60:161–170.
  14. Vernazza PL, Gilliam BL, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997; 11:1249–1254.
  15. Pereira AS, Kashuba AD, Fiscus SA, et al. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis 1999; 180:2039–2043.
  16. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415–421.
  17. Townsend CL, Byrne L, Cortina-Borja M, et al. Earlier initiation of ART and further
  18. decline in mother-to-child HIV transmission rates, 2000-2011. AIDS 2014; 28:1049-1057.
  19. Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless
  20. sex in serodifferent gay couples with the HIV-positive partner taking suppressive
  21. antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational
  22. study. Lancet 2019; 39310189):2428-2438.
  23. Bavinton BR, Jin F, Prestage G, et al. The Opposites Attract Study of viral load, HIV
  24. treatment and HIV transmission in serodiscordant homosexual male couples: design and
  25. methods. BMC Public Health. 2014; 14:917.
  26. Center for Disease Control and Prevention. Updated U.S Public health service guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for postexposure prophylaxis. MMWR 2001; Vol. 50, issue RR‐11.
  27. Centers for Disease Control and Prevention. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood-France, United Kingdom, and United States, January 1988-August 1994. MMWR 1995; 44:929–933.
  28. Australian Government Department of Health and Ageing. National guidelines for post-exposure prophylaxis after non-occupational exposure to HIV. URL (last accessed on 25 April 2018): http://www.ashm.org.au/pep-guidelines.
  29. Roland ME, Neilands TB, Krone M et al. Seroconversion following non-occupational postexposure prophylaxis against HIV. Clin Infect Dis 2005; 41:1507-1513.
  30. Jochimsen EM, Luo CC, Beltrami JF, et al. Investigations of possible failures of postexposure prophylaxis following occupational exposures to human immunodeficiency virus. Arch Intern Med 1999; 159:2361-2363.
  31. Tsai C-C, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl)adenine treatment for prevention of persistent simian immunodeficiency virus SIVmneinfection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-73.
  32. Roland ME, Neilands TB, Krone M,  et al. Seroconversion following non-occupational postexposure prophylaxis against HIV. Clin Infect Dis 2005; 41:1507-1513.
  33. Ford N, Irvine C, Shubber Z, et al. Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis. AIDS 2014; 28:2721-2727.
  34. Ford N and Mayer KH for the World Health Organization postexposure prophylaxis guideline development group. World Health Organization guidelines on postexposure prophylaxis for HIV: recommendations for a public health approach. CID 2015; 60:S161-S163.
  35. Post-exposure prophylaxis to prevent HIV infection. Joint WHO/ILO guidelines on post-exposure prophylaxis (PEP) to prevent HIV infection Geneva, Switzerland. WHO, 2007. URL (last accessed on 25 April 2018): http://www.who.int/hiv/pub/prophylaxis/pep_guidelines/en/.
  36. McAllister J, Read P, McNulty A, Tong WWY and Carr A. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. HIV Med 2014; 1:13-22.
  37. Foster R, McAllister J, Read TR, et al. Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure in Men Who Have Sex with Men. Clin Infect Dis 2015; 61:1336-41.
  38. McAllister J, Towns J, McNulty A et al. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV post-exposure prophylaxis in gay and bisexual men [abstract]. In: Proceedings of 21st International AIDS Conference; 2016, Jul 18-22; Durban, South Africa: Abstract WEPEC231.
  39. Truvada Prescribing information. Gilead Sciences, Inc. Foster City, CA 94404. URL (last accessed on 30 October 2019): https://www.gilead.com/-/media/files/pdfs/medicines/hiv/truvada/truvada_pi.pdf.
  40. Grulich AE, Guy R, Amin J et al, EPIC-NSW research group. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV. 2018; 5:e629-e637.
  41. NSW Government eHealth. Rural eHealth. URL(last accessed on 24 August 2019): http://www.ehealth.nsw.gov.au/programs/clinical/rural.

Developing a sustainable HIV, Viral Hepatitis and Sexual Health Workforce

Information

About ASHMFeedback
Glossary of TermsPrivacy Policy
AcknowledgementsDisclosure Statements

Acknowledgement of Country

We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.

ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2024 ASHM

Scroll to Top